Maternal vitamin D status in early pregnancy is crucial for fetal growth and may reduce the risk of preterm birth, according ...

Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

The company is currently preparing for Phase III trials to further assess the efficacy and safety of the agent in identifying ...

Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas Pharmaceuticals"), focused on the development ...

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 2,210,000 shares, ...

The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference p ...

Signs and symptoms of age-related macular degeneration (AMD) are important to spot to prevent further deterioration of sight.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...